CardioExchange Archive

July 11th, 2014

Do FFR and IVUS Feed the Elephant?

Richard A. Lange, MD, MBA and L. David Hillis, MD

Rick Lange and David Hillis wonder whether the debate about the role of FFR and IVUS in patient selection for PCI is a red herring in the larger issue of revascularization in patients with stable CAD.

---

June 28th, 2013

More Bad News for HDL Therapies: ASSURE Trial Misses Primary Endpoint

Larry Husten, PHD

The string of bad news for HDL-related therapies continues. Resverlogix yesterday announced that the ASSURE clinical trial had failed to meet its primary endpoint. RVX-208, the drug being studied in the trial, is a novel small molecule that increases production of Apolipoprotein A-I (ApoA-1), which raises HDL levels and is thought to enhance reverse cholesterol transport. ASSURE was a […]

---

November 15th, 2011

SATURN Regression Trial: Gorilla Statin and Statin King Battle to a Draw

Larry Husten, PHD

An epic battle comparing the two most potent statins — the reigning king atorvastatin versus “gorilla statin” rosuvastatin — has ended with a quiet draw. Results of SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: Effect of Rosuvastatin Versus AtorvastatiN) were presented at the AHA on Tuesday and published simultaneously in the New England Journal of Medicine. Stephen Nicholls and colleagues randomized 1039 […]

---

September 2nd, 2011

Rosuvastatin Fails to Best Atorvastatin in IVUS Study of Atherosclerosis Progression

Larry Husten, PHD

AstraZeneca announced today that its lipid-lowering agent rosuvastatin (Crestor) was not superior to atorvastatin (Lipitor, Pfizer) in reducing the progression of atherosclerosis, as assessed by IVUS. The company announced the top-line results of SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: Effect of Rosuvastatin Versus AtorvastatiN), which is scheduled to be presented at the American Heart Association meeting in November. The […]

---

January 19th, 2011

What PROSPECT Doesn’t Tell Us

Richard A. Lange, MD, MBA and L. David Hillis, MD

The PROSPECT trial provides some interesting insights about the mechanisms of thrombotic coronary artery disease, but how, if at all, should it change practice? Here are what the findings do and do not demonstrate: What the PROSPECT study says: In ACS patients treated with PCI, major adverse cardiovascular events that occurred during a median follow-up of 3.4 years were as […]

---